Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university’s Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was selected to receive the money after pitching its business plan in a live competition.
University of Chicago Associate VP for Entrepreneurship and Innovation John Flavin said, “The Innovation Fund enables entrepreneurs to transform discoveries into tangible products and services that have an impact on people’s lives. Our investments this fall will help these ventures establish a clear path to market for their inventive ideas addressing important biomedical and energy related challenges.”
Read the Innovation Fund press release.
